Ixempra® (ixabepilone) is a cell-cycle specific antimicrotubule agent. It attaches to a section of the microtubule and thereby acts on the microtubule structure and function of the cell. Thereby the microtubular function is stabilized and ultimately cause cell death.
How it Works
Already before Oncology Venture obtained the option to in-license Ixempra®, more than 80 studies involving ixabepilone have been completed.
A molecular model of ixabepilone.
According to Oncology Venture’s analysis patients benefiting from Ixempra® can be identified by using Oncology Venture’s ixabepilone-specific DRP® companion diagnostic. A dedicated DRP® for Ixempra® is still to be developed.